One-time Delivery of APCs with Kynurenic Acid

Combining systemic administration of KynA with a one-time delivery of APCs, BirchBioMed is developing a pioneering therapeutic approach tailored for specific autoimmune conditions like Type 1 Diabetes and Alopecia Areata. This innovative strategy, currently in clinical trials for two indications, employs dual-action therapy to directly modulate the autoimmune response. AI-001 aims to recalibrate the immune system, potentially offering a transformative solution for managing and treating certain complex subsets of clinical autoimmune conditions.

*Planned initiation of the clinical trial.